
Immunic Inc (IMUX) Stock Forecast & Price Target
Immunic Inc (IMUX) Analyst Ratings
Bulls say
Immunic is a clinical-stage biopharmaceutical company with a promising pipeline of selective oral immunology therapies that target chronic inflammatory and autoimmune diseases like ulcerative colitis, Crohn's disease, multiple sclerosis, and psoriasis. The company has a strong focus on safety and efficacy factors in their treatment selection, and their lead product candidate, vidofludimus calcium, has shown promising results in Phase 2 clinical trials for relapsing-remitting multiple sclerosis (RRMS). They also have a robust research and development program for other indications like secondary progressive MS (SPMS) and primary progressive MS (PPMS), which have high unmet medical needs and large addressable markets. With a clean safety profile and potential market penetration in the RMS market, Immunic has the potential for significant upside and a favorable patient benefit/risk profile compared to current treatment options.
Bears say
Immunic is a clinical-stage biopharmaceutical company with a negative outlook, primarily due to concerns about the success of its pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases such as ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company's current products, IMU-838, IMU-935, and IMU-856, target specific immune pathways but have shown limitations in previous clinical trials. Additionally, the company faces potential competition and limited market penetration in the highly competitive and crowded field of multiple sclerosis treatments. Financially, Immunic has a high cash burn rate and may require additional funding in the future to continue development. The recent hiring of a new CMO and Vice President of Business Development does not guarantee success, and there is potential for significant downside risk in the stock price if clinical trials do not meet expectations.
This aggregate rating is based on analysts' research of Immunic Inc and is not a guaranteed prediction by Public.com or investment advice.
Immunic Inc (IMUX) Analyst Forecast & Price Prediction
Start investing in Immunic Inc (IMUX)
Order type
Buy in
Order amount
Est. shares
0 shares